Skip to main content
ARVN
NASDAQ Life Sciences

Arvinas 10-Q: $558.9M Cash Funds Operations Into 2H 2028 After $53.9M Q3 Loss

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$7.09
Mkt Cap
$463.588M
52W Low
$6.74
52W High
$14.51
52W Position info
5.2% above low
Off High info
51% below high
Rel. Volume info
2.2× avg
Market data snapshot near publication time

ARVN is trading near its 52-week low of $6.74 (5.2% above the low) on elevated volume (2.2× avg).

Summary

Arvinas ended Q3 2026 with $558.9M in cash and securities, enough to fund operations into the second half of 2028, while posting a $53.9M quarterly loss on $0.5M of royalty revenue. The 10-Q also discloses that the ARV-102 PSP trial remains on FDA clinical hold.


Key Events · Earnings and Guidance · ARVN

  • Q3 Loss of $53.9M on $0.5M Revenue

    Third-quarter 2026 net loss was $53.9M, or $0.82 per share, versus a $35.1M loss a year earlier; revenue was $0.5M of sales-based royalties under the Rigel License Agreement.

  • Cash of $558.9M, Runway Into 2H 2028

    Cash, cash equivalents, restricted cash and marketable securities totaled $558.9M at September 30, 2026, which management says funds planned operating expenses and capital expenditures into the second half of 2028.

  • Nine-Month Operating Cash Use Halved

    Net cash used in operations was $127.9M for the nine months ended September 30, 2026, versus $243.4M a year earlier, helped by $57.9M of nine-month net income and lower spending.

  • ARV-102 PSP Trial Still on FDA Hold

    The planned Phase 1b trial of ARV-102 in progressive supranuclear palsy remains on clinical hold pending FDA review; Arvinas plans an EU CTA in Q4 2026 and a UK CTA in Q1 2027, with trial initiation in 2027.


Analysis · ARVN · Life Sciences

The headline loss was already out this morning, but the 10-Q is where the balance sheet and runway live: $558.9M of cash, restricted cash and marketable securities at September 30, which management says funds planned operations into the second half of 2028. For a clinical-stage company with no product revenue of its own, that runway is the core of the thesis — VEPPANU is now Rigel's to commercialize, and Arvinas booked only $0.5M of sales-based royalties in the quarter. Cost cuts are doing real work: R&D fell to $46.9M from $64.7M and G&A to $12.6M from $21.0M year over year, and nine-month operating cash use improved to $127.9M from $243.4M. The offset is that the pipeline now carries the story, and one program is stalled — the ARV-102 Phase 1b trial in PSP is on clinical hold while the FDA reviews, pushing the EU and UK trial starts to 2027.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ARVN was trading at $7.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $463.6M. The 52-week trading range was $6.74 to $14.51. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ARVN - Latest Insights

ARVN
Nov 03, 2026, 8:09 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.06
Real-time Price: $6.76 info
Change: -$0.300 (-4%) info
Market Cap: $443.661M info
ARVN
Nov 03, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $7.52
Real-time Price: $6.76 info
Change: -$0.760 (-10%) info
Market Cap: $443.661M info
ARVN
Oct 07, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $7.52
Real-time Price: $6.76 info
Change: -$0.760 (-10%) info
Market Cap: $443.661M info
ARVN
Sep 28, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $7.60
Real-time Price: $6.76 info
Change: -$0.840 (-11%) info
Market Cap: $443.661M info
ARVN
Aug 04, 2026, 4:08 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $9.00
Real-time Price: $6.76 info
Change: -$2.24 (-25%) info
Market Cap: $443.661M info